Introduction
Hirschsprung's disease (HSCR), also called aganglionic megacolon, is a hereditable disease of the enteric nervous system. 1, 2 It is an embryonic developmental disorder characterized by the absence of ganglion cells which are derived from the neural crest in the lower digestive tract. Due to the absence of enteric plexus, gut motility is seriously compromised in HSCR patients, resulting in intestinal obstruction. There is a racial and ethnic variation in the prevalence of HCRS, and it is more often found among Asians as compared with Caucasians (2.8 vs. 2 per 10,000 live births). About 20% of HSCR cases are familial ones, with considerable genetic diversity in HSCR arising either because of locus or allelic heterogeneity. Studies of the genetic bases of HSCR have identified several disease-causing genes, including RET (receptor tyrosine kinase, 10q11.2), [3] [4] [5] [6] [7] GDNF (glial cell derived neurotrophic factor, 5p12-3.1), 8, 9 NTN (neurturin, 10q13.3), 10 EDN3 (endothelin 3, 20q13.2), 11 and EDNRB (G protein-coupledendothelin receptor B, 13q22). 12 In the case of RET mutation in several families, the HSCR phenotype was found to cosegregate with MEN2A, particularly when the RET gene mutation is in codon 618 or 620. 3 Thus, the clinical manifestations of RET mutations are highly dependent on the location of the mutation.
Heterozygous germline mutations in the RET gene that act as dominant inhibitors account for around 50% of familial HSCR and 7-35% of sporadic HSCR. 5, 7, 13, 14 These mutations include missense, nonsense, deletion, insertion and frameshift mutations and occur throughout the RET gene. 5, 7, [13] [14] [15] Background: Hirschsprung's disease (HSCR), or aganglionic megacolon, is a hereditable disease of the enteric nervous system. It is an embryonic developmental disorder characterized by the absence of ganglion cells in the lower enteric plexus. Gut motility is compromised in HSCR, with consequent risk of intestinal obstruction. Methods: We sequenced the RET gene and characterized the clinical manifestations in 15 unrelated Chinese patients (9 males, 6 females; age range, 2-21 years) with sporadic HSCR. Genomic DNA extraction, PCR and DNA sequence analysis were performed according to standard procedures. Results: We identified heterozygous RET gene mutations in 2 patients. The mutations included a missense mutation in exon 2 (CGC CAC) resulting in a substitution of arginine by histidine at codon 67 (patient 1), and a missense mutation in exon 3 (TAC AAC) resulting in a substitution of tyrosine by asparagine at codon 146 (patient 2). The pathological findings disclosed short-segment HSCR in patient 1 and long-segment HSCR in patient 2, respectively. HSCR is due, in part, to the loss of RET function or a reduced amount of RET protein. Previous studies found the prevalence of RET gene mutations among patients with sporadic HSCR to be 14.3% in Japanese 16 and 19% in southern Chinese. 15 In contrast, the prevalence of RET gene mutations among patients with sporadic HSCR has been reported to be as low as 3.6% in Taiwan, 17 far below the global average. To address this discrepancy, we investigated the RET gene in 15 Chinese with HSCR in Taiwan.
Methods

Patients
Fifteen unrelated Han Chinese (9 males, 6 females; age range, 2-21 years) with sporadic HSCR were studied. Some of them have been described in a previously published report. 18 The clinical diagnosis of HSCR was based on previously described criteria. 2 An additional 50 unrelated normal Han Chinese subjects were recruited as controls to determine whether any sequence changes might be a common polymorphism. Demographic data and a detailed family history were obtained by an interview with each patient and their family members. This study was approved by the institutional review board of the hospital, and informed consent was obtained from each individual.
Analysis of the RET gene
Genomic DNA was isolated from EDTA-preserved whole blood using the GFX Genomic Blood DNA purification kit (Amersham Biosciences, Piscataway, NJ, USA). The 21 coding exons of the RET gene were amplified by polymerase chain reaction using primers and conditions as described previously 16, 19, 20 or modified empirically (Table 1) 
Mutation confirmation
We used restriction analysis to confirm the presence of mutations in the RET gene. Restriction endonucleases were selected on the basis of whether a mutation created or destroyed a restriction endonuclease site. Digested PCR products were analyzed by electrophoresis on 12.5% polyacrylamide gels with fragments visualized by a silver staining kit (Amersham Pharmacia Biotech AB, Uppsala, Sweden). If the mutation neither created nor destroyed any restriction endonuclease site, we sequenced 50 unrelated normal subjects to study whether the DNA variation was a common polymorphism.
Results
The clinical features, pathologic findings and mutational analyses of all the individuals are shown in Table 2 and Figure 1 . We identified heterozygous missense mutation in the RET gene in 2 of 15 patients. The mutations found were a point mutation in exon 2 (CGC CAC) resulting in a substitution of arginine by histidine at codon 67 (patient 1) and a point mutation in exon 3 (TAC AAC) resulting in a substitution of tyrosine by asparagine at codon 146 (patient 2). The pathological finding disclosed short-segment HSCR in patient 1 and long-segment HSCR in patient 2. The R67H mutation neither created nor destroyed any restriction endonuclease site, so we sequenced 50 normal subjects and found that it is not a common polymorphism. The Y146N mutation destroys the restriction site for AccI. The D489N variation in family 3 was considered to be polymorphic as in D571N variation, which has been reported in 7% of individuals in a Korean population. 21 There were no relationships between the specific mutations with clinical features of HSCR disease (sex, age at onset, length of anatomic involvement).
Discussion
The R67H mutation that we identified in patient 1 has been previously reported in a 5-year-old Japanese girl with central hypoventilation syndrome, chronic intestinal pseudo-obstruction and intractable hypoglycemia in infancy, 22 and is not present in the normal population. Thus, R67H in the RET allele is likely to be disease-causing.
Patient 2 had a novel heterozygous mutation at codon 146 of exon 3 (TAC AAC) that resulted in a substitution of tyrosine by asparagine. Evidence that the Y146N mutation was related causally to HSCR in this patient is based on the following: (1) the Y146 residue is highly conserved in human, chimpanzee, dog, rat, mouse, and chicken RET genes, suggesting that substitutions at these codons are not tolerated; (2) this base change was not found in 50 unrelated subjects, suggesting that it is not a common polymorphism; (3) the amino acid changes from hydrophobic amino acid to polar amino acid with an uncharged R group. Since both parents of patient 2 were normal in both phenotype and genotype, this mutation most likely arose de novo in this subject. The R67H and Y146N mutations resulted in short-segment and long-segment HSCR, respectively. Both mutations alter amino acids that are in the extracellular portion of the RET proto-oncogene. Amino acid substitution in the extracellular domain (class I mutation) has been predicted to impair RET maturation and prevent protein from reaching the cell surface, 23 and might alter protein folding and cause inappropriate intracellular trafficking. 24, 25 However, there does not appear to be a significant relationship between the specific missense mutations or their location with specific clinical features of HSCR disease (sex, age of onset, length of anatomical involvement) in this or another study. 15 In contrast with the low frequency of RET gene mutations previously observed in patients with HSCR disease in Taiwan, 17 we found a more typical prevalence (13.3%) of RET mutations in this study despite the small number of subjects analyzed. This discrepancy probably reflects an ascertainment bias. Compared with the RET gene mutations in southern Han Chinese with HSCR, 15 we found no similar mutations in the Han Chinese in Taiwan.
In conclusion, we have identified 2 missense mutations in the RET gene in 15 patients with HSCR disease in Taiwan. The Y146N mutation we identified was novel.
